Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study--trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01).
Fiche publication
Date publication
septembre 2003
Journal
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr COUDERT Bruno, Pr MERROUCHE Yacine, Pr PIVOT Xavier, Dr KAMINSKY Marie-Christine
Tous les auteurs :
Culine S, Lortholary A, Voigt JJ, Bugat R, Théodore C, Priou F, Kaminsky MC, Lesimple T, Pivot X, Coudert B, Douillard JY, Merrouche Y, Allouache J, Goupil A, Négrier S, Viala J, Petrow P, Bouzy J, Laplanche A, Fizazi K,
Lien Pubmed
Résumé
To evaluate the efficacy and toxicity of novel chemotherapy combinations including cisplatin with gemcitabine (GC) or irinotecan (IC) for patients with carcinomas of an unknown primary site.
Mots clés
Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, adverse effects, Camptothecin, administration & dosage, Cisplatin, administration & dosage, Deoxycytidine, administration & dosage, Female, Humans, Male, Middle Aged, Neoplasms, Unknown Primary, drug therapy
Référence
J. Clin. Oncol.. 2003 Sep;21(18):3479-82